Granted Patent
B2
US 12,551,455 · App. 18/375,787 · Granted Feb 17, 2026
Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
Assignee:
AXCESS GLOBAL SCIENCES, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and/or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.
Claims (43)
1 . A composition for administering ketone bodies to a subject, comprising:
at least one beta-hydroxybutyrate compound selected from the group consisting of beta-hydroxybutyrate salt and beta-hydroxybutyrate free acid; and
at least one acetoacetate compound selected from the group consisting of acetoacetate salt and acetoacetate free acid,
wherein the composition comprises:
about 55% to about 95% by weight of the at least one beta-hydroxybutyrate compound; and
about 5% to about 45% by weight of the at least one acetoacetate compound.
2 . The composition of claim 1 , wherein the composition comprises:
about 5% to about 25% by weight of the at least one acetoacetate compound when the subject is not NAD+ deficient; or
about 5% to about 25% by weight of the at least one acetoacetate compound when the subject is deficient in NAD+.
3 . The composition of claim 1 , wherein the at least one beta- hydroxybutyrate compound comprises a plurality of beta-hydroxybutyrate salts selected from the group consisting of sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, and amino acid beta-hydroxybutyrate.
4 . The composition of claim 1 , wherein the at least one acetoacetate compound comprises a plurality of acetoacetate salts selected from the group consisting of sodium acetoacetate, potassium acetoacetate, magnesium acetoacetate, calcium acetoacetate, and amino acid acetoacetate.
5 . The composition of claim 1 , further comprising at least one ketone body ester selected from the group consisting of beta-hydroxybutyrate esters and acetoacetate esters.
6 . The composition of claim 5 , wherein the ketone body ester comprises at least one of a mono-ester of ethanol, a mono-ester of 1-propanol, a mono-ester of 1,3-propanediol, a di-ester of 1,3-propanediol, a mono-ester of 1,3-butanediol, di-ester of 1,3-butanediol, a mono-ester of glycerin, a di-ester of glycerin, or a tri-ester of glycerin.
7 . The composition of claim 1 , wherein the composition is provided as a beverage.
8 . The composition of claim 1 , wherein the composition is provided as a mouth spray or energy shot.
9 . The composition of claim 1 , wherein the composition is provided as a powder, liquid, gel, suspension, tablet, capsule, food product, food additive, beverage additive, or food supplement.
10 . The composition of claim 1 , wherein the composition is free of medium chain fatty acids.
11 . A kit for administering ketone bodies to a subject, comprising:
a composition comprising at least one beta-hydroxybutyrate compound selected from the group consisting of beta-hydroxybutyrate salt and beta-hydroxybutyrate free acid and at least one acetoacetate compound selected from the group consisting of acetoacetate salt and acetoacetate free acid, wherein the composition comprises:
about 55% to about 95% by weight of the at least one beta-hydroxybutyrate compound; and
about 5% to about 45% by weight of the at least one acetoacetate compound;
a container in which the composition is placed, wherein the container is one or more of a carton, a box, a can, a jar, a bag, a pouch, a jug, or a keg; and
a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 0.5 g to about 50 g of combined beta-hydroxybutyrate and acetoacetate salts, wherein the measuring device is one or more of a cup, a scoop, a syringe, a spoon, or a spatula.
12 . The kit of claim 11 , wherein:
the at least one beta-hydroxybutyrate compound comprises a plurality of beta-hydroxybutyrate salts selected from the group consisting of sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, transition metal beta-hydroxybutyrate, and amino acid beta-hydroxybutyrate.
13 . The kit of claim 11 , wherein the at least one acetoacetate compound comprises a plurality of acetoacetate salts selected from the group consisting of sodium acetoacetate, potassium acetoacetate, magnesium acetoacetate, calcium acetoacetate, transition metal acetoacetate, and amino acid acetoacetate.
14 . The kit of claim 11 , wherein the composition is free of medium chain fatty acids.
15 . A composition for administering ketone bodies to a subject by oral ingestion, the composition comprising:
at least one beta-hydroxybutyrate compound selected from the group consisting of beta-hydroxybutyrate salt and beta-hydroxybutyrate free acid; and
at least one acetoacetate compound comprising one or more acetoacetate salts and optionally acetoacetate free acid,
wherein the composition is formulated for oral ingestion and provided as a solid, powder, tablet, capsule, food product, solid food additive, solid beverage additive, or solid food supplement.
16 . The composition of claim 15 , further comprising one or more ketone body esters selected from the group consisting of beta-hydroxybutyrate esters and acetoacetate esters.
17 . The composition of claim 15 , wherein the at least one beta-hydroxybutyrate compound comprises a plurality of beta-hydroxybutyrate salts selected from the group consisting of sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, and calcium beta-hydroxybutyrate.
18 . The composition of claim 15 , wherein the at least one acetoacetate compound comprises a plurality of acetoacetate salts selected from the group consisting of sodium acetoacetate, potassium acetoacetate, magnesium acetoacetate, and calcium acetoacetate.
19 . The composition of claim 15 , wherein the composition comprises:
about 55% to about 95% by weight of the at least one beta-hydroxybutyrate compound; and
about 5% to about 45% by weight of the at least one acetoacetate compound.
20 . A composition for administering ketone bodies to a subject, the composition comprising:
at least one beta-hydroxybutyrate compound selected from the group consisting of beta-hydroxybutyrate salt and beta-hydroxybutyrate free acid; and
at least one acetoacetate compound comprising one or more acetoacetate salts and optionally acetoacetate free acid,
wherein the composition comprises:
about 55% to about 95% by weight of the at least one beta-hydroxybutyrate compound; and
about 5% to about 45% by weight of the at least one acetoacetate compound.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 2, 2023
From: MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 065096/0763 →
Continuity (4)
Provisional Application
62659564
· Apr 18, 2018
References Cited (400)
US 2238149A
· Aeckerle
· 1941
[cited by applicant]
US 2976073A
· Russell et al.
· 1961
[cited by applicant]
US 4139761A
· Obrowski
· 1979
[cited by applicant]
US 4224503A
· Gijzel et al.
· 1980
[cited by applicant]
US 4292499A
· Kleinschmidt et al.
· 1981
[cited by applicant]
US 4627808A
· Hughes
· 1986
[cited by applicant]
US 4663166A
· Veech
· 1987
[cited by examiner]
US 4771074A
· Lammerant et al.
· 1988
[cited by applicant]
US 4969393A
· Mahlich et al.
· 1990
[cited by applicant]
US 4997976A
· Brunengraber et al.
· 1991
[cited by applicant]
US 5093044A
· Wretlind et al.
· 1992
[cited by applicant]
US 5100677A
· Veech
· 1992
[cited by applicant]
US 5116868A
· Chen et al.
· 1992
[cited by applicant]
US 5288512A
· Seiden
· 1994
[cited by applicant]
US 5292774A
· Hiraide et al.
· 1994
[cited by applicant]
US 5654266A
· Chen et al.
· 1997
[cited by applicant]
US 5700670A
· Yamagishi et al.
· 1997
[cited by applicant]
US 6207856B1
· Veech
· 2001
[cited by applicant]
US 6217915B1
· Luchansky et al.
· 2001
[cited by applicant]
US 6232345B1
· Hiraide et al.
· 2001
[cited by applicant]
US 6316038B1
· Veech
· 2001
[cited by applicant]
US 6323237B1
· Veech
· 2001
[cited by applicant]
US 6380244B2
· Martin et al.
· 2002
[cited by applicant]
US 6613356B1
· Vlahakos
· 2003
[cited by applicant]
US 6706756B1
· Fitzpatrick et al.
· 2004
[cited by applicant]
US 6835750B1
· Henderson
· 2004
[cited by applicant]
US 7351736B2
· Veech
· 2008
[cited by applicant]
US 7807718B2
· Hashim et al.
· 2010
[cited by applicant]
US 7891287B2
· Miller
· 2011
[cited by applicant]
US 8101653B2
· Veech
· 2012
[cited by applicant]
US 8124589B2
· Henderson
· 2012
[cited by applicant]
US 8344896B2
· Ozanne
· 2013
[cited by applicant]
US 8426468B2
· Henderson
· 2013
[cited by applicant]
US 8642654B2
· Clarke et al.
· 2014
[cited by applicant]
US 8748400B2
· Henderson
· 2014
[cited by applicant]
US 9138420B2
· D'Agostino
· 2015
[cited by third party]
US 9211275B2
· Clarke et al.
· 2015
[cited by applicant]
US 9435566B2
· Hill et al.
· 2016
[cited by applicant]
US 9675577B2
· D'Agostino et al.
· 2017
[cited by applicant]
US 9717767B2
· Carpenter et al.
· 2017
[cited by applicant]
US 9795580B2
· Weeber et al.
· 2017
[cited by applicant]
US 9808481B2
· Ritter et al.
· 2017
[cited by applicant]
US 9925164B1
· Hashim
· 2018
[cited by applicant]
US 9957246B2
· Stinchcomb et al.
· 2018
[cited by applicant]
US 20010014696A1
· Veech
· 2001
[cited by applicant]
US 20010018866A1
· Fischer
· 2001
[cited by applicant]
US 20010041736A1
· Veech
· 2001
[cited by applicant]
US 20020013339A1
· Martin et al.
· 2002
[cited by applicant]
US 20030022937A1
· Veech
· 2003
[cited by applicant]
US 20040126366A1
· Kaddurah-Daouk
· 2004
[cited by third party]
US 20040138293A1
· Werner et al.
· 2004
[cited by applicant]
US 20050129783A1
· McCleary et al.
· 2005
[cited by applicant]
US 20060275253A1
· Ushida et al.
· 2006
[cited by applicant]
US 20070135376A1
· Henderson
· 2007
[cited by applicant]
US 20070179197A1
· Henderson
· 2007
[cited by applicant]
US 20080058416A1
· Greenwood et al.
· 2008
[cited by applicant]
US 20090253781A1
· Veech
· 2009
[cited by applicant]
US 20100041751A1
· Henderson
· 2010
[cited by applicant]
US 20100056631A1
· Hisamura et al.
· 2010
[cited by applicant]
US 20120053240A1
· Rathmacher et al.
· 2012
[cited by applicant]
US 20120071548A1
· Veech
· 2012
[cited by applicant]
US 20120202891A1
· Stinchcomb et al.
· 2012
[cited by applicant]
US 20130079406A1
· Veech
· 2013
[cited by applicant]
US 20130337116A1
· Petralia
· 2013
[cited by applicant]
US 20140256808A1
· Henderson
· 2014
[cited by applicant]
US 20140329893A1
· Veech
· 2014
[cited by applicant]
US 20140352728A1
· Svensson
· 2014
[cited by applicant]
US 20150065571A1
· Clarke et al.
· 2015
[cited by applicant]
US 20150363750A1
· Svensson et al.
· 2015
[cited by applicant]
US 20170298339A1
· Hanson et al.
· 2017
[cited by applicant]
US 20180021281A1
· Berger
· 2018
[cited by applicant]
US 20180055797A1
· Llosa et al.
· 2018
[cited by applicant]
US 20180057846A1
· Llosa et al.
· 2018
[cited by applicant]
US 20190099394A1
· Ari et al.
· 2019
[cited by applicant]
US 20190209501A1
· Tinsley, M. et al.
· 2019
[cited by applicant]
US 20190313682A1
· Nagel
· 2019
[cited by applicant]
US 20200268701A1
· D'Agostino et al.
· 2020
[cited by applicant]
US 20210106168A1
· Cingolani et al.
· 2021
[cited by applicant]
US 20230201145A1
· Gary
· 2023
[cited by applicant]
US 20230346721A1
· Millet
· 2023
[cited by applicant]
CA 2990927A1
· 2018
[cited by applicant]
CN 86108978A
· 1987
[cited by applicant]
CN 1256629A
· 2000
[cited by applicant]
CN 1347319A
· 2002
[cited by applicant]
CN 1972698A
· 2007
[cited by applicant]
CN 101674730A
· 2010
[cited by applicant]
CN 101678043A
· 2010
[cited by applicant]
CN 101969769A
· 2011
[cited by applicant]
CN 102164884A
· 2011
[cited by applicant]
CN 104224823A
· 2014
[cited by applicant]
CN 105050594A
· 2015
[cited by applicant]
CN 106038532A
· 2016
[cited by applicant]
CN 106459646A
· 2017
[cited by applicant]
CN 106858066A
· 2017
[cited by applicant]
CN 108253621A
· 2018
[cited by applicant]
CN 109480284A
· 2019
[cited by applicant]
CN 111867576A
· 2020
[cited by applicant]
CN 112262936A
· 2021
[cited by applicant]
DE 102017210992A1
· 2019
[cited by applicant]
EP 0008700A1
· 1980
[cited by applicant]
EP 1112711A1
· 2001
[cited by applicant]
EP 1178748A1
· 2002
[cited by applicant]
EP 1827412A1
· 2007
[cited by applicant]
EP 1915144A2
· 2008
[cited by applicant]
EP 2283834A2
· 2011
[cited by applicant]
EP 2976073A1
· 2016
[cited by applicant]
EP 3094321A1
· 2016
[cited by applicant]
EP 3366173A2
· 2018
[cited by applicant]
EP 3446045A1
· 2019
[cited by applicant]
FR 2997302A1
· 2014
[cited by applicant]
GB 2391493A
· 2004
[cited by applicant]
ID 201701176
· 2017
[cited by applicant]
JP 11060434A
· 1999
[cited by applicant]
JP 2002521330A
· 2002
[cited by applicant]
JP 2004035417A
· 2004
[cited by applicant]
JP 5030553B2
· 2012
[cited by applicant]
JP 2015042644A
· 2015
[cited by applicant]
JP 2015514104A
· 2015
[cited by applicant]
JP 2015102323A
· 2015
[cited by applicant]
JP 2016514725A
· 2016
[cited by applicant]
JP 2016121128A
· 2016
[cited by applicant]
JP 2017046688A
· 2017
[cited by applicant]
JP 2018158897A
· 2018
[cited by applicant]
JP 2020502652A
· 2020
[cited by applicant]
JP 2020527583A
· 2020
[cited by applicant]
JP 2021504476A
· 2021
[cited by applicant]
JP 2021506294A
· 2021
[cited by applicant]
RU 2345546C2
· 2009
[cited by applicant]
WO 8703808A1
· 1987
[cited by applicant]
WO 9841200A1
· 1998
[cited by applicant]
WO 0069315A1
· 2000
[cited by applicant]
WO 0370823A2
· 2003
[cited by applicant]
WO 2005107724A1
· 2005
[cited by applicant]
WO 2006061624A1
· 2006
[cited by applicant]
WO 2007115282A2
· 2007
[cited by applicant]
WO 2008005818A1
· 2008
[cited by applicant]
WO 2008021394A2
· 2008
[cited by applicant]
WO 2008024408A2
· 2008
[cited by applicant]
WO 2009089144A1
· 2009
[cited by applicant]
WO 2010021766A1
· 2010
[cited by applicant]
WO 2011101171A1
· 2011
[cited by applicant]
WO 2012019295A1
· 2012
[cited by applicant]
WO 2013057506A1
· 2013
[cited by applicant]
WO 2013150153A1
· 2013
[cited by applicant]
WO 2014153416A1
· 2014
[cited by applicant]
WO 2015071811A1
· 2015
[cited by applicant]
WO 2015156865A1
· 2015
[cited by applicant]
WO 2016123229A1
· 2016
[cited by applicant]
WO 2016149687A1
· 2016
[cited by applicant]
WO 2017156446A1
· 2017
[cited by applicant]
WO 2017165443A1
· 2017
[cited by applicant]
WO 2017165445A1
· 2017
[cited by applicant]
WO 2017182664A1
· 2017
[cited by applicant]
WO 2017208217A2
· 2017
[cited by applicant]
WO 2018055388A1
· 2018
[cited by applicant]
WO 2018089863A1
· 2018
[cited by applicant]
WO 2018114309A1
· 2018
[cited by applicant]
WO 2018175879A1
· 2018
[cited by applicant]
WO 2018187324A1
· 2018
[cited by applicant]
WO 2018187852A1
· 2018
[cited by applicant]
WO 2019018683A1
· 2019
[cited by applicant]
WO 2019104082A1
· 2019
[cited by applicant]
WO 2019108683A1
· 2019
[cited by applicant]
WO 2019118624A1
· 2019
[cited by applicant]
WO 2019204148A1
· 2019
[cited by applicant]
WO 2019237152A1
· 2019
[cited by applicant]
WO 2019237185A1
· 2019
[cited by applicant]
WO 2020041871A1
· 2020
[cited by applicant]
WO 2021178547A1
· 2021
[cited by applicant]
A New Toy Measuring Blood Ketones. Diet Doctor, Aug. 21, 2012. Dowloaded Apr. 1, 2015. http://www.dietdoctor.com/a-new-toy-measuring-blood-ketoones.
[cited by applicant]
Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions in Vivo, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (Apr. 1, 2002)…
[cited by applicant]
Amazon, “Perfect Keto Perform Pre Workout Powder—Bum Fat for Fuel Energy Supplement Drink Mix for Men and Women—Keto Friendly with Ketone Salts, BCAA, Nitric Oxide & MCT”, Sep. 25, 2017 entire document especially p. 1 R…
[cited by applicant]
Anonymous: “Blue Lemon Ice Advanced Formula”, MINTEL, Database accession No. 4315637, 2016, pp. 3.
[cited by applicant]
Anonymous: “Strawberry Pineapple Flavour Pre-Exertion Performance Optimizer”, MINTEL, Database accession No. 5661617, 2018, pp. 4.
[cited by applicant]
Arendash et al. “Caffeine and Coffee as Therapeutics Against Alzheimer's Disease”, Journal of Alzheimer's Disease 20, 2010, S117-S126.
[cited by applicant]
Arnold, Instant Ketosis?, (2013), Aug. 4, 2013 (retrieved on Apr. 21, 2017), p. 1-3. Retrieved from the internet; URL: < http:// patrickarnoldblog.com/instant-ketosis/. (Year: 2013).
[cited by applicant]
Bala et al. Drug Invention Today. Jun. 1, 2018;10(6), 929-931.
[cited by applicant]
Bastin (Organic Process Research and Development, 2000, 4, 427-435).
[cited by applicant]
Bastin et al., “Salt Slection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, American Chemical Society and The Royal Society of Chemistry, vol. 4, No. 5, 2000, pp. 427-435.
[cited by applicant]
Blazquez et al. Journal of Neurochemistry, 1999, vol. 72 No. 4, pp. 1759-1768. (Year: 1999).
[cited by applicant]
Budin. N. et al., “Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S,S) enantiomer,” Bioorganic Chemistry, vol. 80, Oct. 2018, pp. 560-564.
[cited by applicant]
Clarke, et al., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. Aug. 2012;63(3):401-8.
[cited by applicant]
Craciun, S. et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme, 2012, PNAS, 109(52): 21307-21312 (Year: 2012).
[cited by applicant]
Cresci, G. et al., Lactobacillus GG and Tributyrin Supplementation Reduce Antibiotic-Induced Intestinal Injury, 2013, Journal of Parenteral and Enteral Nutrition, 37(6), 1-20 (Year: 2013).
[cited by applicant]
Dietary Guidelines Recommendations at https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/ appendix-7/ (2010) (retrieved from the internet Oct. 20, 2020) (Year: 2010).
[cited by applicant]
Dolson, Laura. How to Test Your Blood for Ketones. Downloaded Apr. 1, 2015. http://lowcarbdiets.about.com/od/KetogenicDiets/a/How-to-Test-Blood-For-Ketones.htm.
[cited by applicant]
Enhancing Human Performance: Ketones. Blue Sky Fact Finding Meeting, Oct. 24, 2012.
[cited by applicant]
European Search Report received for EP Patent Application No. 20755289.4, mailed on Oct. 11, 2022, 7 pages.
[cited by applicant]
European Search Report received for EP Patent Application No. 20755994.9, mailed on Sep. 21, 2022, 6 pages.
[cited by applicant]
European Search Report received for EP Patent Application No. 20805593.9, mailed on Dec. 16, 2022, 9 pages.
[cited by applicant]
Extended European Search Report issued in PCT/US2017021886 dated Oct. 17, 2019.
[cited by applicant]
Extended European Search Report pursuant to Rule 62 EPC (EPO Form 1507S) issued on Jan. 24, 2017 for corresponding European Patent Application No. 14770025.6.
[cited by applicant]
Extended European Search Report received for EP Patent Application No. 19788264.0, mailed on Dec. 20, 2021, 11 pages.
[cited by applicant]
Extended European Search Report received for EP Patent Application No. 20755770.3, mailed on Sep. 1, 2022, 7 pages.
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 711433 issued by the New Zealand Intellectual Property Office dated Mar. 10, 2016.
[cited by applicant]
First Office Action issued by the Chinese State Intellectual Property Office on Nov. 4, 2016 for corresponding Chinese Patent Application No. 201480016818.0.
[cited by applicant]
Grootaert, C. Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem, 2009, FEMS Microbiology Ecology, 69: 231-242 (Year: 2009).
[cited by applicant]
Haces M L et al: “Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions”, Experimental Neurology, Elsevier, Amsterdam, NL, vol. 211, No. 1, May 1…
[cited by applicant]
Hashim, Sarni A., et al., “Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester”, Journal of Lipid Research, vol. 55, 2014.
[cited by applicant]
Haywood A, Glass BD. Pharmaceutical excipients—where do we begin? Australian Prescriber. 2011; 34: 112-114.
[cited by applicant]
Henderson, Samuel T. “Ketone Bodies as a Therapeutic for Alzheimer's Disease.” Neurotherapeutics. Jul. 2008;5(3):470-80.
[cited by applicant]
Holscher, H. Dietary fiber and prebiotics and the gastrointestinal microbiota, 2017, Gut Microbes, 8(2): 172-184 (Year: 2017).
[cited by applicant]
Holtzman et al., “Role of adenosine receptors in caffeine tolerance”, J. Pharmacol. Exp. Ther., 1991 ;256(1 ):62-68.
[cited by applicant]
Huang Dexiang et al., “Clinical Intravenous Nutrition”, Shanghai Medical University Press Jan. 31, 1994, pp. 121-124.
[cited by applicant]
Huang Dexiang, “Clinical Parenteral nutrition”, Jan. 31, 1994, pp. 1-20.
[cited by applicant]
Ichim, T. et al., Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome, 2016, Journal of Translational Medicine, 14(184), 1-9 …
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/016952, mailed on Aug. 26, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US20/37289, mailed on Dec. 30, 2021, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/031237, mailed on Oct. 1, 2015, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2017/021886, mailed on Sep. 20, 2018, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062093, mailed on Jun. 4, 2020, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062096, mailed on Jul. 2, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/027214, mailed on Oct. 29, 2020, 09 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/048357, mailed on Mar. 11, 2021, 08 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/048364, mailed on Mar. 11, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017552, mailed on Aug. 26, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017555, mailed on Aug. 26, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/017556, mailed on Aug. 26, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/033159, mailed on Nov. 25, 2021, 6 pages.
[cited by applicant]
Mangels D.R. et al., “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763.
[cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, Vo. Dec. 30, 2016.
[cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005).
[cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956.
[cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/.
[cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits.com.au/ketosis-can-we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017).
[cited by applicant]
Parker, Steve, “Ketogenic Mediterranean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010).
[cited by applicant]
Partial supplementary European search report (EPO Form 1507US) issued by the European Patent Office on Sep. 21, 2016 for corresponding European Application No. 14770025.6.
[cited by applicant]
PCT International Search Report and Written Opinion issued by the International Searching Authority on Jul. 15, 2014 or International Patent Application No. PCT/US2014/031237.
[cited by applicant]
Pete J Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9.
[cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin' La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15…
[cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019.
[cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions in Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (…
[cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373.
[cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011).
[cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982.
[cited by applicant]
Sajewicz et al. in Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010).
[cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial…
[cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017).
[cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R.
[cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm.
[cited by applicant]
Shigeno etal. in Biosci. Biotech. Biochem., 56(2), 320-323 (1992) (Year: 1992).
[cited by applicant]
Short, Jay, Effects of a Ketone/Caffeine Supplement on Cycling and Cognitive Performance, Master's thesis, Ohio State University, 61 pages, (Jan. 1, 2017).
[cited by applicant]
Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits, 2013, Nutrients, 5: 1417-1425 (Year: 2013).
[cited by applicant]
Sorensen et al. (“Simultaneous determination of ß-hydroxybutyrate and ß-hydroxy-ß-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry”, Clinical …
[cited by applicant]
Stubbs et al., “On the Metabolism of Exogenous Ketones in Humans”, frontiers in Physiology, vol. 8, 2017, 13 pages.
[cited by applicant]
Tanaka, J., et al., “Significance of Blood Ketone Body Ration as an indicator of Hepatic Cellular Energy Status in Jaundiced Rabbits”, Gastroenterology, 1979, vol. 76, No. 4, pp. 691-696.
[cited by applicant]
The Medical Republic, 2018, Sustained Release Sodium Butyrate Supplement Now Available to Support Management of GI Disorders, https://medicalrepublic.com.au/ sustained-release-sodium-butyrate-supplement-now-available-su…
[cited by applicant]
Tisdale, “Reduction of weight loss and tumour size in a cachexia model by a high fat diet”, British Journal of Cancer, Jul. 1987, vol. 56, p. 39-43.
[cited by applicant]
Tsai et al., “Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes” life Sciences 78(2006) pp. 1385-1391.
[cited by applicant]
Vandenberghe et al. in Can. J. Physiol. Pharmacol. 95: 455-458 (2017) (Published at www.nrcresearchpress.com/cjpp on Nov. 25, 2016). (Year: 2016).
[cited by applicant]
Veech, “The Therapeutic Implications of Ketone Bodies: The Effects of Ketone Bodies in Pathological Conditions: Ketosis, Ketogenic Diet, Redox States, Insulin Resistance, and Mitochondrial Metabolism”, Prostaglandins Le…
[cited by applicant]
Veech, et al., “Ketone Bodies Mimic the Life Span Extending Properties of Caloric Restriction”, IUBMB Life Feb. 8, 2017.
[cited by applicant]
Vorgerd, M. and J. Zange. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myologica, 2007; XXVI; pp. 61-63.
[cited by applicant]
Walton, G. et al. A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers, 2012, Nut…
[cited by applicant]
Written Opinion cited in PCT/US19/27214 dated Jun. 25, 2019.
[cited by applicant]
Wu et al., “Medium-Chain Triglycerides in Infant Formulas and Their Relation to Plasma Ketone Body Concentrations,” Pediatric Research, vol. 20, No. 4, (1986), pp. 338-341.
[cited by applicant]
Yang Y. et al., Role of Adherent-Invasive
[cited by applicant]
Yang Yue et al., “Research on sarcopenic obesity”, Chinese Journal of Modern Medicine, vol. 20, No., 3, Mar. 25, 2018, pp. 98-101.
[cited by applicant]
Yang Zeyi, “Biochemistry of sports nutrition scientific research progress”, Mar. 31, 2004, vol. 23, No. 2, pp. 158-165.
[cited by applicant]
Zaleski, A. et al., Butyric acid in irritable bowel syndrome, 2013, Prz Gastroenterol, 8(6), 350-353 (Year: 2013).
[cited by applicant]
Zeng Jing et al., “B-hydroxy-3-methyl—The clinical effects and mechanism”, vol. 2, No. 2, Jun. 9, 2015, pp. 57-62.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/017078, mailed on Aug. 18, 2022, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/045186, mailed on Mar. 9, 2023, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/050302, mailed on Mar. 2, 2023, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/063559, mailed on Jul. 6, 2023, 6 pages.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US19/48357 dated Nov. 18, 2019.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US19/48364 dated Nov. 15, 2019.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/16952 dated Apr. 22, 2020.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/17552 dated May 4, 2020.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/17555 dated May 4, 2020.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/17556 dated May 4, 2020.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/062093, mailed on Feb. 1, 2019, 7 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US20/017555, mailed on May 4, 2020, 8 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US20/37289, mailed or Sep. 30, 2020, 8 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/031237, mailed on Jul. 15, 2014, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2017/021886, mailed on Jun. 1, 2017, 15 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/062096, mailed on Feb. 11, 2019, 13 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/027214, mailed on Jun. 25, 2019, 14 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/048357, mailed on Nov. 18, 2019, 13 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/016952, mailed on Apr. 22, 2020, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/017552, mailed on May 4, 2020, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/017556, mailed on May 4, 2020, 12 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/033159, mailed on Aug. 12, 2020, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/063559, mailed on Mar. 18, 2022, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/045186, mailed on Nov. 22, 2021, 10 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/17078, mailed on Apr. 23, 2021, 9 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/17078, mailed or Apr. 23, 2021, 9 pages.
[cited by applicant]
International Search Report cited in PCT/US18/62093 dated Feb. 1, 2019.
[cited by applicant]
International Search Report cited in PCT/US18/62096 dated Feb. 11, 2019.
[cited by applicant]
International Search Report cited in PCT/US19/27214 dated Jun. 25, 2019.
[cited by applicant]
Invitation to Respond to Written Opinion issued by the Intellectual Property Office of Singapore dated Dec. 28, 2016 for corresponding Singapore Patent Application No. 11201506780R.
[cited by applicant]
It Really is in Your Blood: Glucose to Ketone Ratios. Greymadder, Sep. 15, 2014. Downloaded Apr. 1, 2015. http://greymadder.net/2014/09/15/it-really-is-in-your-blood-glucose-to-ketone-ratios/.
[cited by applicant]
James, “Optical Purity and Enantiomeric Excess” at https://www.master organicchemistry.com/2017/02/24/optical-purity-and-enantiomeric-excess/. (Retrieved from the internet Nov. 6, 2018) (Year: 2018).
[cited by applicant]
John C Newman et al: “beta-Hydroxybutyrate: A Signaling Metabolite”, Annual Review of Nutrition, vol. 37, Aug. 21, 2017 (Aug. 21, 2017), pp. 51-76, XP055771586.
[cited by applicant]
Karppanen et al, J. Human Hypertension (2005), vol. 19, pp. S10-S19. (Year: 2005).
[cited by applicant]
Karppanen, H., et al., “Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets?” J. Human Hypertension (2005), vol. 19, pp. S10-S19.
[cited by applicant]
Kaster M.P. et al., “Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress”, Proceedings of the National Academy of Sciences, vol. 112, No. 25, Jun. 8,…
[cited by applicant]
Kesl, et al., “Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Spraque-Dawley rats”, Nutrition & Metabolism (2016).
[cited by applicant]
Kim Do Young et al., “Ketone bodies are protective against oxidative stress in neocortical neurons,” Journal of Neurochemistry, vol. 101, Issue 5, Jun. 1, 2007, pp. 1316-1326.
[cited by applicant]
Kirsch, Jr et al. “Butanediol Induced Ketosis Increases Tolerance to Hypoxia in the Mouse.” Stroke. 1980, vol. 11, No. 3, pp. 506-513.
[cited by applicant]
Kossoff, Eric H. et al. “Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group.” Epilepsia, Feb. 2009;50(2):304-17. Epub Sep. 2, 20083.
[cited by applicant]
Krotkiewski, “Value of VLCD Supplementation with Medium Chain Triglycerides”, Int J Obes Relat Metab Disord, Sep. 2001, 25(9), pp. 1393-1400.
[cited by applicant]
Lang Chaochun, “Healthy fitness and exercise prescription”, Nov. 30, 2013, p. 201.
[cited by applicant]
Lile et al. Drug Alcohol Depend. 2012, 122 (1-2), 61-69.
[cited by applicant]
Lonza, Duocap Capsules, Feb. 16, 2018, https ://web .archive.org/web/20180216001656/https://www.capsugel.com/consumer-health-nutrition-products/duocap-capsules (Year: 2018).
[cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieved from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15.
[cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491.
[cited by applicant]
Maalouf Met al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar. …
[cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315.
[cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev…
[cited by applicant]
Malo, M. S. et al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010).
[cited by applicant]
European Search Report received for EP Patent Application No. 21862356.9, mailed on Jul. 1, 2024, 10 pages.
[cited by applicant]